نتائج البحث

Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

• Authors : Taguchi S; Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.; Kawai T

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/drug therapy ; Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/Carcinoma, Transitional Cell*/pathology

• Source: BJU international [BJU Int] 2024 Jul; Vol. 134 (1), pp. 43-44. Date of Electronic Publication: 2023 Dec 18.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.

• Authors : Welsh SJ; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/diagnostic imaging ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy

• Source: BJU international [BJU Int] 2022 Aug; Vol. 130 (2), pp. 244-253. Date of Electronic Publication: 2021 Nov 02.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).

• Authors : Dhiantravan N; Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Subjects: Clinical Trials, Phase II as Topic* ; Randomized Controlled Trials as Topic* ; Research Design*

• Source: BJU international [BJU Int] 2021 Sep; Vol. 128 (3), pp. 331-342. Date of Electronic Publication: 2021 Apr 21.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.

• Authors : Moe A; University of Western Australia (UWA) Medical School, University of Western Australia, Perth, WA, Australia.; Urology and Medical Oncology Departments, South Metropolitan Health Service, Perth, WA, Australia.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*administration & dosage ; Urinary Bladder Neoplasms/Urinary Bladder Neoplasms/Urinary Bladder Neoplasms/*drug therapy

• Source: BJU international [BJU Int] 2021 Oct; Vol. 128 Suppl 1, pp. 9-17. Date of Electronic Publication: 2021 May 06.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).

• Authors : Rodriguez-Vida A; Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.; Bamias A

Subjects: Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/administration & dosage ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/adverse effects ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/therapeutic use

• Source: BJU international [BJU Int] 2020 Nov; Vol. 126 (5), pp. 559-567. Date of Electronic Publication: 2020 Aug 02.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer.

• Authors : Lee SH; Department of Pharmacy, National University of Singapore, Singapore City, Singapore.; Mahendran R

Subjects: Acetamides*/Acetamides*/Acetamides*/pharmacology ; Acetamides*/Acetamides*/Acetamides*/therapeutic use ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology

• Source: BJU international [BJU Int] 2020 Nov; Vol. 126 (5), pp. 554-556. Date of Electronic Publication: 2020 Aug 29.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.

• Authors : Shamash J; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.; Mee M

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Brain Neoplasms/Brain Neoplasms/Brain Neoplasms/*drug therapy ; Neoplasms, Germ Cell and Embryonal/Neoplasms, Germ Cell and Embryonal/Neoplasms, Germ Cell and Embryonal/*drug therapy

• Source: BJU international [BJU Int] 2020 Jun; Vol. 125 (6), pp. 843-852. Date of Electronic Publication: 2020 May 04.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.

• Authors : Madan RA; Genitourinary Malignancies Branch, NCI, Bethesda, MD, USA.; Karzai FH

Subjects: Anilides/Anilides/Anilides/*administration & dosage ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use

• Source: BJU international [BJU Int] 2021 Apr; Vol. 127 (4), pp. 435-444. Date of Electronic Publication: 2020 Oct 23.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

• Authors : De Giorgi U; Cartenì G ...

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Bone Neoplasms/Bone Neoplasms/Bone Neoplasms/*drug therapy ; Brain Neoplasms/Brain Neoplasms/Brain Neoplasms/*drug therapy

• Source: BJU international [BJU Int] 2019 Jan; Vol. 123 (1), pp. 98-105. Date of Electronic Publication: 2018 Jul 23.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Enhanced taxane uptake into bladder tissues following co‐administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes.

• Authors : Pandey, Rakhi¹ ; Jackson, John K.¹; Liggins, Richard²

• Source: BJU International. Nov2018, Vol. 122 Issue 5, p898-908. 11p.

تفاصيل العنوان